Head-to-head evidence
Phenytoin vs Zonisamide (Zonegran)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channels · full Epilepsy pipeline
Phenytoin
Marketed by Viatris and partners
NCT00210782 · Phase 3 · completed
The study was a randomized, double-blind comparison of topiramate and phenytoin involving 262 participants, using the clinical endpoint of time to first seizure. Because the registry does not report whether the primary comparison was statistically significant, the trial provides a well-designed but currently inconclusive evidence base.
Next expected readout: December 2026 · NCT05637086 (registry estimate)
Zonisamide (Zonegran)
Marketed by Advanz Pharma and partners
NCT00056576 · Phase 3 · completed
Although 165 participants were reportedly randomized and treatment was double-blinded, the study is listed as a single-group design with no placebo or active comparator. No primary endpoint or results are posted, so whether the primary outcome was met or missed cannot be assessed.
Next expected readout: July 2027 · NCT06967012 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Phenytoin's landscape · Zonisamide (Zonegran)'s landscape